Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

被引：8
作者：
Ding, Yuping [1 ,2 ]
Deng, Quanjun [1 ,2 ]
Yang, Mei [1 ,2 ]
Niu, Haiyan [1 ,2 ]
Wang, Zuoyu [1 ,2 ]
Xia, Shihai [1 ,2 ,3 ,4 ]
机构：
[1] Chinese Peoples Armed Police Force, Dept Gastroenterol & Hepatol, Characterist Med Ctr, Tianjin 300162, Peoples R China
[2] Tianjin Key Lab Hepatopancreat Fibrosis & Mol Diag, Tianjin 300162, Peoples R China
[3] Chinese Peoples Armed Police Force, Dept Gastroenterol & Hepatol, Characterist Med Ctr, 220 Chenglin Rd, Tianjin 300162, Peoples R China
[4] Tianjin Key Lab Hepatopancreat Fibrosis & Mol Diag, 220 Chenglin Rd, Tianjin 300162, Peoples R China
来源：
DIABETES METABOLIC SYNDROME AND OBESITY | 2023年 / 16卷
关键词：
obesity; metabolic dysfunction-associated fatty liver disease; phenotypes; type 2 diabetes mellitus; treatment; weight loss; NORMAL-WEIGHT OBESITY; HEALTHY OBESITY; BARIATRIC SURGERY; SARCOPENIC OBESITY; BODY-FAT; INDEPENDENT PREDICTOR; INSULIN-RESISTANCE; NATURAL-HISTORY; ADIPOSE-TISSUE; UNITED-STATES;
D O I：
10.2147/DMSO.S431251
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Obesity,and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically to increase the risk of adverse clinical outcomes (both hepatic and extrahepatic). Type 2 diabetes mellitus (T2DM) is the most important risk factor for rapid progression of steatohepatitis and advanced fibrosis. Conversely, the later stages of MAFLD are associated with an increased risk of T2DM incident. According to the proposed criteria, MAFLD is diagnosed in patients with liver steatosis and in at least one in three: overweight or obese, T2DM, or signs of metabolic dysregulation if they are of normal weight. However, the clinical classification and correlation between obesity and MAFLD is more complex than expected. In addition, treatment for obesity and MAFLD are associated with a reduced risk of T2DM, suggesting that liver-based treatments could reduce the risk of developing T2DM. This review describes the clinical classification of obesity and MAFLD, discusses the clinical features of various types of obesity and MAFLD, emphasizes the role of visceral obesity and insulin resistance (IR) in the development of MAFLD,and summarizes the existing treatments for obesity and MAFLD that reduce the risk of developing T2DM.
引用
收藏
页码：3303 / 3329
页数：27
相关论文
共 216 条
[1]   Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss [J].
Al-Mrabeh, Ahmad ;
Zhyzhneuskaya, Sviatlana V. ;
Peters, Carl ;
Barnes, Alison C. ;
Melhem, Shaden ;
Jesuthasan, Aaron ;
Aribisala, Benjamin ;
Hollingsworth, Kieren G. ;
Lietz, Georg ;
Mathers, John C. ;
Sattar, Naveed ;
Lean, Michael E. J. ;
Taylor, Roy .
CELL METABOLISM, 2020, 31 (02) :233-+
[2]   Phenotypes of Sarcopenic Obesity: Exploring the Effects on Peri-Muscular Fat, the Obesity Paradox, Hormone-Related Responses and the Clinical Implications [J].
Alalwan, Tariq A. .
GERIATRICS, 2020, 5 (01)
[3]   American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons [J].
Ali, Mohamed R. ;
Moustarah, Fady ;
Kim, Julie J. .
SURGERY FOR OBESITY AND RELATED DISEASES, 2016, 12 (03) :462-467
[4]   Dietary and Biochemical Characteristics Associated with Normal-Weight Obesity [J].
Amani, Reza ;
Parohan, Mohammad ;
Jomehzadeh, Nabi ;
Haghighizadeh, Mohammad Hossein .
INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2019, 89 (5-6) :331-336
[5]   The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity [J].
Ampuero, Javier ;
Aller, Rocio ;
Gallego-Duran, Rocio ;
Banales, Jesus M. ;
Crespo, Javier ;
Garcia-Monzon, Carmelo ;
Pareja, Maria Jesus ;
Vilar-Gomez, Eduardo ;
Caballeria, Juan ;
Escudero-Garcia, Desamparados ;
Gomez-Camarero, Judith ;
Calleja, Jose Luis ;
Latorre, Mercedes ;
Albillos, Agustin ;
Salmeron, Javier ;
Aspichueta, Patricia ;
Lo Iacono, Oreste ;
Frances, Ruben ;
Benlloch, Salvador ;
Fernandez-Rodriguez, Conrado ;
Garcia-Samaniego, Javier ;
Estevez, Pamela ;
Andrade, Raul J. ;
Turnes, Juan ;
Romero-Gomez, Manuel .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (11-12) :1260-1270
[6]   Metabolically Healthy Obesity Redefined [J].
April-Sanders, Ayana K. ;
Rodriguez, Carlos J. .
JAMA NETWORK OPEN, 2021, 4 (05)
[7]   Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis [J].
Argo, C. K. ;
Stine, J. G. ;
Henry, Z. H. ;
Lackner, C. ;
Patrie, J. T. ;
Weltman, A. L. ;
Caldwell, S. H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (03) :290-299
[8]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690
[9]   Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups [J].
Ayada, Ibrahim ;
van Kleef, Laurens A. ;
Alferink, Louise J. M. ;
Li, Pengfei ;
de Knegt, Robert J. ;
Pan, Qiuwei .
LIVER INTERNATIONAL, 2022, 42 (02) :277-287
[10]   Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease [J].
Badmus, Olufunto O. ;
Hinds, Terry D. ;
Stec, David E. .
CURRENT HYPERTENSION REPORTS, 2023, 25 (08) :151-162
12345678910